Novartis Heart Drug Fails Late-Stage Study, Adding to Pipeline Setbacks

Novartis AG suffered a second trial setback in a week after its potential blockbuster heart drug failed in a final-stage study, according to Bloomberg. The result deepens pipeline setbacks for the Swiss drugmaker and comes as rivals are also affected.